Yan Li1, Musaddiq J Awan2, Tangel Chang3, Pierre Lavertu4, Chad Zender4, Rod Rezaee4, Nicole Fowler4, Jay Wasman5, Norbert E Avril6, Nianyong Chen1, Mitchell Machtay7, Min Yao7. 1. Department of Radiation Oncology, West China Hospital of Sichuan University, Chengdu, China. 2. Department of Radiation Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA. muawan@gmail.com. 3. Department of Radiation Oncology, University of Toledo, Toledo, OH, USA. 4. Department of Otolaryngology and Head and Neck Surgery, University Hospitals, Cleveland, OH, USA. 5. Department of Pathology, University Hospitals, Cleveland, OH, USA. 6. Department of Nuclear Medicine and Radiology, University Hospitals, Cleveland, OH, USA. 7. Department of Radiation Oncology, Case Western Reserve University and University Hospitals, Cleveland, OH, USA.
Abstract
PURPOSE: The purpose of this study was to retrospectively review the role of post-treatment (post-tx) FDG-PET/CT scans in patients receiving postoperative intensity-modulated radiotherapy (IMRT) for head and neck squamous cell carcinomas (HNSCC). MATERIALS AND METHODS: Eighty-two patients with HNSCC treated with surgery and postoperative IMRT with or without chemotherapy from October 15, 2008 to December 31, 2014 that had post-tx PET/CT within 6 months of completing IMRT were included. PET/CT was considered positive based on multi-disciplinary review integrating clinical information. Survival analysis was performed using the Kaplan-Meier method. Categorical and continuous predictors of positive post-tx PET/CT were evaluated using Fisher's exact test and logistic regression, respectively. Predictors for survival outcomes were evaluated with log-rank testing. A p ≤ 0.05 was considered statistically significant. RESULTS: Median follow-up was 3.88 years. For all patients, 3-year overall survival (OS) and recurrence-free survival (RFS) were 71.8% and 61.3%, respectively. Patients with positive post-tx PET/CT had worse OS compared to those with negative post-tx PET/CT (log rank p < 0.001). For patients with positive post-tx PET/CT, 3-year OS was 11.2% compared to 89.9% for patients with negative post-tx PET/CT. The positive predictive value (PPV) of PET/CT was 100% for local recurrence (LR), regional recurrence (RR) and distant metastasis (DM). The negative predictive values (NPV) for LR, RR and DM were 89.0%, 89.2%, and 85.9%, respectively. Perineural invasion (p = 0.009), p16 status (p = 0.009), non-oropharyngeal primary site (p = 0.002), and the use of chemotherapy (p = 0.01) were independent predictors of positive PET/CT. CONCLUSIONS: Post-tx PET/CT after postoperative radiation is prognostic for survival outcomes. The PPV of post-tx PET for recurrence was excellent, allowing for early detection of recurrent disease. Post-tx PET/CT should be considered after postoperative radiation.
PURPOSE: The purpose of this study was to retrospectively review the role of post-treatment (post-tx) FDG-PET/CT scans in patients receiving postoperative intensity-modulated radiotherapy (IMRT) for head and neck squamous cell carcinomas (HNSCC). MATERIALS AND METHODS: Eighty-two patients with HNSCC treated with surgery and postoperative IMRT with or without chemotherapy from October 15, 2008 to December 31, 2014 that had post-tx PET/CT within 6 months of completing IMRT were included. PET/CT was considered positive based on multi-disciplinary review integrating clinical information. Survival analysis was performed using the Kaplan-Meier method. Categorical and continuous predictors of positive post-tx PET/CT were evaluated using Fisher's exact test and logistic regression, respectively. Predictors for survival outcomes were evaluated with log-rank testing. A p ≤ 0.05 was considered statistically significant. RESULTS: Median follow-up was 3.88 years. For all patients, 3-year overall survival (OS) and recurrence-free survival (RFS) were 71.8% and 61.3%, respectively. Patients with positive post-tx PET/CT had worse OS compared to those with negative post-tx PET/CT (log rank p < 0.001). For patients with positive post-tx PET/CT, 3-year OS was 11.2% compared to 89.9% for patients with negative post-tx PET/CT. The positive predictive value (PPV) of PET/CT was 100% for local recurrence (LR), regional recurrence (RR) and distant metastasis (DM). The negative predictive values (NPV) for LR, RR and DM were 89.0%, 89.2%, and 85.9%, respectively. Perineural invasion (p = 0.009), p16 status (p = 0.009), non-oropharyngeal primary site (p = 0.002), and the use of chemotherapy (p = 0.01) were independent predictors of positive PET/CT. CONCLUSIONS: Post-tx PET/CT after postoperative radiation is prognostic for survival outcomes. The PPV of post-tx PET for recurrence was excellent, allowing for early detection of recurrent disease. Post-tx PET/CT should be considered after postoperative radiation.
Entities:
Keywords:
Head and neck cancer; PET/CT; Postoperative radiotherapy; Prognostic factors
Authors: Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke Journal: N Engl J Med Date: 2004-05-06 Impact factor: 91.245
Authors: Min Yao; Michael M Graham; Russell B Smith; Kenneth J Dornfeld; Mark Skwarchuk; Henry T Hoffman; Gerry F Funk; Scott M Graham; Yusuf Menda; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2004-12-01 Impact factor: 7.038
Authors: Min Yao; Russell B Smith; Michael M Graham; Henry T Hoffman; Huaming Tan; Gerry F Funk; Scott M Graham; Kristi Chang; Kenneth J Dornfeld; Yusuf Menda; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2005-08-15 Impact factor: 7.038
Authors: K K Ang; A Trotti; B W Brown; A S Garden; R L Foote; W H Morrison; F B Geara; D W Klotch; H Goepfert; L J Peters Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: Jacques Bernier; Jay S Cooper; T F Pajak; M van Glabbeke; J Bourhis; Arlene Forastiere; Esat Mahmut Ozsahin; John R Jacobs; J Jassem; Kie-Kian Ang; J L Lefèbvre Journal: Head Neck Date: 2005-10 Impact factor: 3.147
Authors: Jayakar V Nayak; Rohan R Walvekar; Regiane S Andrade; Nicole Daamen; Stephen Y Lai; Athanassios Argiris; Ryan P Smith; Dwight E Heron; Robert L Ferris; Jonas T Johnson; Barton F Branstetter Journal: Laryngoscope Date: 2007-12 Impact factor: 3.325
Authors: Stephanie A Shintani; Robert L Foote; Val J Lowe; Paul D Brown; Yolanda I Garces; Jan L Kasperbauer Journal: Int J Radiat Oncol Biol Phys Date: 2007-09-24 Impact factor: 7.038
Authors: Min Yao; Russell B Smith; Henry T Hoffman; Gerry F Funk; Minggen Lu; Yusuf Menda; Michael M Graham; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-17 Impact factor: 7.038
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481